A virtual meeting of the National Drug Scheduling Advisory Committee (NDSAC) was held on March 5, 2023 with the following interim recommendations made:

• Loratadine and its salts and preparations in products labelled for use in children aged 2 to 11 years, in package sizes containing greater than 140mg of loratadine, remain in Schedule III
• Loratadine and its salts and preparations in products labelled for use in children aged 2 to 11 years, in package sizes containing no more than 140mg of loratadine, be granted Unscheduled status
• Loratadine and its salts and preparations, in products labelled for use in individuals 12 years of age and older, remain Unscheduled

Any objections to these interim recommendations must be received by the NAPRA office by end of day April 12, 2023. Questions or comments should be directed to the NDSAC Secretariat via email at ndsac@napra.ca.